Why ImmunityBio is on investors’ radar today

ImmunityBio (IBRX) is drawing fresh attention after recent trading left the stock at a last close of US$7.24, with investors weighing sizable past losses against strong multi-year total return figures and updated fundamentals.

The share price has cooled recently, with a 1 day move down of 3.72% and a 90 day share price decline of 27.6%. However, the year to date share price return of 258.42% and 1 year total shareholder return of 171.16% still point to strong momentum built over the past year, despite longer term 5 year total shareholder returns being down 52.99%.

If ImmunityBio’s surge has you thinking about what else could be moving, this is a good moment to scan for other healthcare related opportunities through 40 healthcare AI stocks.

With ImmunityBio trading at US$7.24 against an analyst price target of US$13.00 and an indicated intrinsic discount of around 80%, the key question is whether this signals a genuine opportunity or if markets are already pricing in future growth.

Most Popular Narrative: 46.4% Undervalued

ImmunityBio’s most followed narrative pegs fair value at $13.50 per share, well above the last close at $7.24. This frames the current discount as substantial.

The rapid global expansion of ANKTIVA into 33 countries, including the U.S., EU, U.K., and Saudi Arabia, together with commercial partners like Accord and regional distributors, sets up a much larger treated patient base over time, which is directly tied to future product revenue growth.

Want to see what is behind that valuation gap? Revenue built on one core therapy, bold earnings targets and a rich future profit multiple all sit in this narrative.

Result: Fair Value of $13.50 (UNDERVALUED)

However, this story can change quickly if ANKTIVA remains concentrated in bladder cancer, or if regulators slow or restrict approvals across those 33 target markets.

Next Steps

Seeing both risk and reward in this story, it makes sense to move quickly, review the underlying data yourself, and pressure test the thesis using the 3 key rewards and 4 important warning signs

Looking for more investment ideas?

If ImmunityBio has caught your attention, do not stop here. Broaden your watchlist with other focused stock ideas that could sharpen your next move.

• Spot opportunities that the market might be overlooking by scanning a curated set of screener containing 22 high quality undiscovered gems.
• Prioritise resilience and sleep easier at night by reviewing companies in the 62 resilient stocks with low risk scores.
• Zero in on companies that pair financial strength with quality operations using the solid balance sheet and fundamentals stocks screener (45 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.